PT - JOURNAL ARTICLE AU - David M.G. Halpin AU - Sally Worsley AU - Afisi S. Ismaila AU - Kai-Michael Beeh AU - Dawn Midwinter AU - Janwillem W.H. Kocks AU - Elaine Irving AU - Jose M. Marin AU - Neil Martin AU - Maggie Tabberer AU - Neil G. Snowise AU - Chris Compton TI - INTREPID: single- <em>versus</em> multiple-inhaler triple therapy for COPD in usual clinical practice AID - 10.1183/23120541.00950-2020 DP - 2021 Apr 01 TA - ERJ Open Research PG - 00950-2020 VI - 7 IP - 2 4099 - http://openres.ersjournals.com/content/7/2/00950-2020.short 4100 - http://openres.ersjournals.com/content/7/2/00950-2020.full SO - erjor2021 Apr 01; 7 AB - Introduction Real-world trial data comparing single- with multiple-inhaler triple therapy (MITT) in COPD patients are currently lacking. The effectiveness of once-daily single-inhaler fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) and MITT were compared in usual clinical care.Methods INTREPID was a multicentre, randomised, open-label, phase IV effectiveness study comparing FF/UMEC/VI 100/62.5/25 µg via the ELLIPTA inhaler with a clinician's choice of any approved non-ELLIPTA MITT in usual COPD clinical practice in five European countries. Primary end-point was proportion of COPD Assessment Test (CAT) responders (≥2-unit decrease in CAT score from baseline) at week 24. Secondary end-points in a subpopulation included change from baseline in forced expiratory volume in 1 s (FEV1) and percentage of patients making at least one critical error in inhalation technique at week 24. Safety was also assessed.Results 3092 patients were included (FF/UMEC/VI n=1545; MITT n=1547). The proportion of CAT responders at week 24 was significantly greater with FF/UMEC/VI versus non-ELLIPTA MITT (OR 1.31, 95% CI 1.13–1.51; p&lt;0.001) and mean change from baseline in FEV1 was significantly greater with FF/UMEC/VI (77 mL versus 28 mL; treatment difference 50 mL, 95% CI 26–73 mL; p&lt;0.001). The percentage of patients with at least one critical error in inhalation technique was low in both groups (FF/UMEC/VI 6%; non-ELLIPTA MITT 3%). Safety profiles, including incidence of pneumonia serious adverse events, were similar between treatments.Conclusions In a usual clinical care setting, treatment with once-daily single-inhaler FF/UMEC/VI resulted in significantly more patients gaining health status improvement and greater lung function improvement versus non-ELLIPTA MITT.Once-daily single-inhaler treatment with FF/UMEC/VI results in greater improvements in health status and lung function compared with non-ELLIPTA multiple-inhaler triple therapy in patients with COPD in a usual clinical practice setting https://bit.ly/2PHXNwU